{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:26:10Z","timestamp":1793719570946,"version":"4.6.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.kint.2019.09.033","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T19:33:03Z","timestamp":1572636783000},"page":"393-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes"],"prefix":"10.1016","volume":"97","author":[{"given":"Eugene Yu-hin","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazel","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Ghiggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison Lap-tak","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Desheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Tullus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.09.033_bib1","first-page":"39","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Front Ped"},{"key":"10.1016\/j.kint.2019.09.033_bib2","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","article-title":"Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy","volume":"19","author":"Benz","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib3","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.09.033_bib4","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.kint.2019.09.033_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","article-title":"Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome","volume":"27","author":"Kemper","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.09.033_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00467-015-3245-9","article-title":"Cyclophosphamide and rituximab in frequently relapsing\/steroid-dependent nephrotic syndrome","volume":"31","author":"Webb","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens\u00a0on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome","volume":"25","author":"Prytu\u0142a","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00431-017-2891-2","article-title":"Variability of diagnostic criteria and treatment of idiopathic nephrotic syndrome across European countries","volume":"176","author":"Desch\u00eanes","year":"2017","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.kint.2019.09.033_bib12","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.krcp.2014.05.017","article-title":"Efficacy and safety of rituximab in children with refractory nephrotic syndrome: a multicenter clinical trial","volume":"33","author":"Ahn","year":"2014","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.kint.2019.09.033_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","article-title":"Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab","volume":"31","author":"Kamei","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","article-title":"Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome","volume":"28","author":"Ito","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","article-title":"Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome","volume":"26","author":"Ito","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.09.033_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","article-title":"Rituximab for nephrotic syndrome in children","volume":"21","author":"Iijima","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kint.2019.09.033_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.kint.2019.09.033_bib20","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","article-title":"Fatal pulmonary fibrosis after rituximab administration","volume":"24","author":"Chaumais","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","article-title":"The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases","volume":"30","author":"Boren","year":"2008","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.kint.2019.09.033_bib22","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","article-title":"Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome","volume":"28","author":"Sellier-Leclerc","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00467-011-1997-4","article-title":"Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome","volume":"27","author":"Sinha","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib24","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor\u2013dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.09.033_bib25","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","article-title":"Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab","volume":"32","author":"Kamei","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12882-018-1099-7","volume":"19","author":"Horinouchi","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-014-3034-x","article-title":"Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome","volume":"30","author":"Fujinaga","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00467-018-3900-z","article-title":"Infusion reactions associated with rituximab treatment for childhood-onset complicated nephrotic syndrome","volume":"33","author":"Kamei","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib29","doi-asserted-by":"crossref","unstructured":"Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol. 2010;47:187\u2013198.","DOI":"10.1053\/j.seminhematol.2010.01.002"},{"key":"10.1016\/j.kint.2019.09.033_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","article-title":"Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome","volume":"28","author":"Sato","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000350681","article-title":"Melanoma and rituximab: an incidental association?","volume":"226","author":"Peuvrel","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.kint.2019.09.033_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/CMR.0000000000000074","article-title":"Four cases of rituximab-associated melanoma","volume":"24","author":"Velter","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1016\/j.kint.2019.09.033_bib33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","article-title":"Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma","volume":"29","author":"Tarella","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2019.09.033_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/ndt\/gfu258","article-title":"Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature","volume":"30","author":"Kamei","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.09.033_bib35","first-page":"139","article-title":"KDIGO clinical practice guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2019.09.033_bib36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10157-016-1328-y","article-title":"Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment","volume":"21","author":"Fujinaga","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib37","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00467-014-2794-7","article-title":"Development of antirituximab antibodies in children with nephrotic syndrome","volume":"29","author":"Ahn","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib38","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00467-013-2546-0","article-title":"Substantial practice variation exists in the management of childhood nephrotic syndrome","volume":"28","author":"Samuel","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2019.09.033_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00467-014-2903-7","article-title":"Best practice guidelines for idiopathic nephrotic syndrome: recommendations versus reality","volume":"30","author":"Pasini","year":"2015","journal-title":"Pediatr Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819310476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819310476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:55:43Z","timestamp":1758761743000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819310476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0085253819310476"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}